Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' ...

A newly designed therapy following an islet cell transplant could mean people with type 1 diabetes no longer need to inject ...

Endocrinologic and Metabolic Drugs Advisory Committee, the majority of panel members voted against the approval of sotagliflozin (Zynquista™) for use as an adjunct to insulin therapy for glycemic ...

Scientists reprogrammed a woman's fat cells to become insulin-making beta cells, reversing her type 1 diabetes.

Islet cell transplantation is used in type 1 diabetes to replace the insulin-producing beta cells that are destroyed by the ...

CHICAGO (CBS) – A groundbreaking treatment for type 1 diabetes is showing promising results for patients in Chicago. It's a ...

A collaboration of researchers led by Emory University Rollins School of Public Health, Atlanta, is urging caution when ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a ...

Off-label SGLT2 inhibitors increase the risk of euglycemic diabetic ketoacidosis. GLP-1RAs may lead to rapid weight loss in ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

and I very much want an adjunctive drug for my patients with type 1 diabetes," said committee chair Cecilia Low Wang, MD, of the University of Colorado in Aurora. The FDA rejected sotagliflozin 5 ...